Genetic marker in vitamin D receptor gene associated with increased pancreatic cancer survival

June 19, 2012

Pancreatic cancer patients with a genetic marker linked to increased expression of the receptor for vitamin D have higher rates of overall survival, according to findings presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

"Based on these findings, we should refocus our attention on the role of the vitamin D pathway in pancreatic cancer because it may have an impact on the survival of patients," said Federico Innocenti, M.D., Ph.D., associate professor of pharmacy at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy.

In a previous study, Innocenti and his colleagues prospectively collected DNA from 365 patients enrolled in the CALGB 80303 randomized phase III clinical trial testing two treatments for advanced pancreatic cancer. A genome-wide association study (GWAS) was conducted using these to identify genetic variations known as single-nucleotide polymorphisms (SNPs) associated with better or worse patient outcome. In the new study, the 300 SNPs previously shown to be most strongly associated with overall survival were tested for their association with overall survival in 408 patients of European descent with advanced pancreatic cancer treated at the Mayo Clinic.

Among the SNPs with concordant effects on overall survival of patients in the CALGB 80303 clinical trial and treated at the Mayo Clinic was a SNP in the for the vitamin D receptor. This SNP, known as rs2853564 in the VDR gene, was associated with better overall survival.

Patients with two copies of rs2853564 in VDR had a median overall survival of 10.5 months in the Mayo Clinic group and 8.9 months in the CALGB 80303 study. Patients with one copy had a median overall survival of 8.34 months in the Mayo Clinic group and 5.9 months in the CALGB 80303 study. Patients with no copies of the variant allele had a median overall survival of 6.6 months in the group and 4.7 months in the CALGB 80303 study.

While Innocenti does not see this study having any immediate clinical implications, he believes it provides more information about the link between vitamin D biology and pancreatic cancer.

Explore further: New study finds two-drug combo slows advanced pancreatic cancer

More information:

Abstract

Role of vitamin D receptor (VDR) gene polymorphisms for overall survival in pancreatic cancer: Genome-wide association and functional mechanistic studies. Federico Innocenti1, Alan P. Venook2, Howard L. McLeod1, Yusuke Nakamura3, Mark J. Ratain4, Gloria M. Petersen5, William R. Bamlet5, Robert R. McWilliams5, Kouros Owzar6, Dylan M. Glubb1, Chen Jiang6, Nancy J. Cox4, Michiaki Kubo3, Hitoshi Zembutsu3, Taisei Mushiroda3, Hedy L. Kindler4. 1University of North Carolina, Chapel Hill, 2University of California at San Francisco, San Francisco, CA, 3RIKEN, Yokohama, Japan, 4University of Chicago, Chicago, IL, 5Mayo Clinic, Rochester, MN, 6Duke University Medical Center, Durham, NC.

Background: Genome-wide association studies (GWAS) are designed to provide novel insights on candidate genes involved in the pathophysiology of cancer and outcome of therapy. We have previously conducted a GWAS in 294 genetic European advanced pancreatic cancer patients treated with gemcitabine in CALGB80303, a phase III randomized clinical trial (Innocenti et al., Clin Cancer Res, 2012;18:577). In the present study, we aim to identify novel genes associated with overall survival (OS) by replicating the most significant single-nucleotide polymorphisms (SNPs) for OS in CALGB80303 in a cohort of pancreatic cancer patients from the Mayo Clinic. We also aim to provide the mechanistic basis for the replicated associations.

Methods: We have selected the top 300 most statistically significant SNPs for OS in CALGB 80303, and tested their association in 408 genetic European advanced pancreatic cancer patients from the Mayo Clinic. The characteristics of the patients in CALGB 80303 are described in our previous publication. Half of the Mayo Clinic patients had locally advanced disease (and half with metastatic disease), about 30% received prior radiation, and about 60% received gemcitabine. They have been genotyped for about 550,000 SNPs using the same Illumina platform of CALGB80303, and the association with OS was tested using a Cox proportional hazard regression model from date of diagnosis to death or last-follow-up.

Results: In the Mayo Clinic patients, we selected 10 SNPs with an effect on OS concordant with CALGB80303 (p<0.05), and 4 of them where located in genes: VDR, CMYA5, C7orf58, CAMK4. Because of the supportive biology of vitamin D and cancer, here we report the results for VDR, the gene coding for the vitamin D receptor. A SNP in VDR (rs2853564) associated with OS in the Mayo Clinic patients (HR 0.82 (95 % CI 0.71-0.95), p=0.0077) and CALGB80303 (HR 0.74 (0.63-0.87), p=0.0002). Patients with 2 variant alleles of rs2853564 have longer median OS survival (10.5 and 8.9 months in the Mayo Clinic and CALGB80303 patients, respectively) than patients with 1 (8.34 and 5.9 months) or 0 (6.6 and 5.7 months) alleles. Using the replication p value as a feature selection to direct translational science, we performed mechanistic studies on VDR. Bioinformatic prediction of the functionality of VDR SNPs indicates that rs2853564 (or SNPs in high linkage disequilibrium with it) might increase VDR expression. In luciferase assays in two cell lines, we have confirmed that the minor allele of rs2853564 increases luciferase expression by 22% (p<0.05) and 37% (p<0.05) in HEK293 and PANC-1 cells, respectively. PANC-1 cells exposed to calcitriol, the hormonally active form of vitamin D, were up to 38% (p=0.0005) less viable than PANC-1 cells which had a siRNA-mediated knockdown of VDR expression.

Conclusions: Efforts of external replications of GWAS, when combined with mechanistic functional studies, are able to direct reverse translational science. In this study, VDR has been selected for further investigation in pancreatic cancer. Calcitriol has several VDR-mediated antitumor properties, and is synergic with gemcitabine in human pancreatic cancer models (Yu et al., Cell Cycle 2010;9:3022).This study proposes that VDR germline variants may modulate VDR expression, resulting in differences in the behavior of pancreatic cancer. The putative prognostic role of VDR germline SNPs should be replicated in additional cohorts of advanced pancreatic cancer patients.

Related Stories

New study finds two-drug combo slows advanced pancreatic cancer

April 3, 2012
The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was ...

Drug improves survival of colorectal cancer patients, trial results show

January 18, 2012
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented ...

Mayo Clinic reports new findings on noninvasive test for pancreatic cancer

May 11, 2011
Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason ...

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 4, 2012
Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.